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Objective: To evaluate the accuracy, feasibility and acceptability of two urine pregnancy tests in assessing abortion outcomes at three time
points after mifepristone administration.
Study design: This randomized trial enrolled women seeking early medical abortion at two hospitals in Vietnam. Investigators randomly
allocated participants to at-home administration of a multilevel urine pregnancy test (MLPT) or a high sensitivity urine pregnancy test
(HSPT) to assess their abortion outcomes. A baseline test was administered on the same day as mifepristone. Participants performed and
interpreted results of pregnancy tests taken 3, 7 and 14 days after mifepristone. Ultrasound exam determined continuing pregnancy.
Results: Six hundred women enrolled, and 300 received each test. A percentage of 97.4 (584) had follow-up, of whom 13 women had
continuing pregnancies. The specificity of MLPT at detecting absence of continuing pregnancy was 63.9%, 90.4% and 97.1% at study day 3,
7 and 14. The specificity of HSPT was 6.0%, 19.8% and 62.2%, respectively. The positive predictive value (PPV) of MLPT at detecting
continuing pregnancy was 6.4% at day 3 and rose to 46.7% at day 14. In contrast, the PPV for HSPT was 2.2% at day 3 and rose to 6.5% at
day 14. At all three time points, the sensitivity and negative predictive values for both tests were 100.0%. Most women found their assigned
tests easy to use and would prefer future home follow-up with a pregnancy test.
Conclusions: The MLPT enables women to assess their abortion outcomes more reliably than with HSPT. With MLPT, women can know
their outcomes as early as 3 days after mifepristone.
Implications: Medical abortion service delivery with an MLPT to obtain a baseline (preabortion) human chorionic gonadotropin (hCG)
estimate and a second follow-up MLPT 1 to 2 weeks later can establish whether there has been a drop in hCG, signifying absence of a
continuing pregnancy. Used this way, MLPTs can enable women to assess their abortion status outside of a clinic setting and without serum
hCG testing and/or ultrasound.
©2016TheAuthors. Published byElsevier Inc. This is an open access article under theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Keywords: Semiquantitative pregnancy test; Multilevel pregnancy test; High sensitivity pregnancy test; Medical abortion; Task shifting; Task sharing1. Introduction
For years, some providers and service delivery systems
have sought to reduce or replace routine clinic-based follow-up☆ Funding: Anonymous donor.
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Researchers have assessed routine serum human chorionic
gonadotropin (hCG) testing [5,6], telephone, text or Internet
follow-up [7–12], home pregnancy testing using high and low
sensitivity pregnancy tests (LSPTs) [7,9,10,12–14] and
multilevel urine pregnancy tests (MLPTs) [15–18].
Home follow-up using commonly available, easy to use
and low-cost urine pregnancy tests has had mixed resultsder theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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mIU/ml or more, and low sensitivity tests usually detect hCG
of either 1000 or 2000 mIU/ml or more. These tests can
produce a high rate of false positive results when used 2
weeks after early medical abortion and are therefore largely
unhelpful in reducing follow-up visits [14]. Serum hCG
testing, although highly efficacious, also has drawbacks: it
can be costly, requires a blood sample at a lab facility and
results are not available right away.
Attempts to improve testing options for abortion
follow-up prompted the development of MLPT, also
known as semiquantitative pregnancy tests. Service delivery
using an MLPT entails obtaining a baseline (preabortion)
hCG estimate and a second, follow-up hCG estimate,
typically 1 to 2 weeks later, to establish whether there has
been a drop in hCG. The MLPT used in this study has
accurately identified both absence and presence of continu-
ing pregnancy when used for medical abortion follow-up at 1
and 2 weeks postmifepristone [15–18].
As hCG levels decrease by about 70% within 24 h after
misoprostol administration for early medical abortion
[19,20], we posited that the MLPT might work for medical
abortion follow-up as early as 2 days after misoprostol. A
shorter process is generally preferable to women, and home
use of MLPT could enable women to assess abortion
outcomes themselves without needing a routine clinic
follow-up visit.
This study sought to evaluate whether hCG trends could
be monitored at home using an MLPT as early as 3 days after
mifepristone.2. Materials and methods
Between June 14, 2013 and February 14, 2014, women
seeking early medical abortion at two hospitals in Vietnam
were randomized to home follow-up with either a multilevel
pregnancy test or a high sensitivity pregnancy test (HSPT).
The institutional ethical review boards at both of the study
hospitals approved this study; the trial is registered at clinical
trials.gov as NCT01856777.
Eligibility criteria included gestational age ≤63 days and
provision of signed informed consent. All women received
ultrasound prior to enrollment per standard practice at the
study sites. Gestational age limits were in accordance with
national guidelines: women ≤63 days were eligible at the
tertiary facility (Hung Vuong Tertiary Hospital in Ho Chi
Minh City), and those≤49 days were eligible at the regional
hospital (HocMon Regional General Hospital in the
periphery of Ho Chi Minh City). Other criteria included
being literate, willing to use up to three home pregnancy tests
and to return to the clinic. After documenting eligibility and
consent, a trained study nurse opened the next sequentially
numbered envelope containing the study group allocation.
Study nurses counseled the women and explained how to
use and interpret the assigned pregnancy test. Participantsthen performed a baseline test on their own at the clinic after
enrollment. After completing the baseline pregnancy test,
each participant received one 200-mg mifepristone tablet to
swallow immediately. Women received four 200-mcg
misoprostol tablets to administer buccally the next day at
home and three pregnancy tests per their study group to take
at home at 3, 7 and 14 days after mifepristone. Women also
received written and pictorial test instructions and a home
diary for recording and interpreting results and abortion
symptoms. The diary cards were returned to the study staff at
follow-up visits. If immediate follow-up was not indicated as
described below, women were instructed to return 2 weeks
after mifepristone.
Women in both groups were asked to use the home test on
study days 3, 7 and 14 and record results.Women in theMLPT
group whose tests showed either a decrease or increase in hCG
after using the test were instructed to return for clinic follow-up
immediately. If hCG levels were unchanged, women were
instructed towait and administer the next scheduled pregnancy
test. Women in the HSPT group with negative results
(hCGb25 mIU/mL) were instructed to return for clinic
follow-up immediately. Women who returned before day 14
andwere found to no longer have a continuing pregnancywere
exited from the study.
In all cases, abortion outcome, including absence of a
continuing pregnancy, was verified using transvaginal
ultrasound and clinical exam within 14 days of mifepristone.
If ultrasound evidence of continuing pregnancy (defined as
continued embryonic/sac growth or continuing fetal cardiac
activity) was identified, immediate additional care was
provided. All other women who sought care due to
uncertainty about their abortion status were given reassur-
ance and additional counseling.
Women who withdrew consent were given appropriate
care and exited the study. If a participant did not return for
clinic follow-up, study staff made at least three attempts to
reach her by phone. During the exit interview, participants
answered questions about the feasibility and acceptability of
using the assigned pregnancy test on their own at home.
The MLPT used was the dBest hCG urine panel test®
(AmeriTek, Seattle WA, USA) [15–18]. Participants were
instructed to dip the test into a urine sample and stir it for at
least 10 s to saturate the strips. They were told to place the
test on a flat surface and read the result approximately
15 min later. The HSPT used was a locally available dipstick
(Quickstick one-step hCG Pregnancy Test®, Phamatech, San
Diego, CA, USA) that showed a “yes” response if hCG was
N25 mIU/mL. Participants were instructed to dip the panel
into a urine sample and read the result 5 min later.
Staff at Gynuity Health Projects in New York who were
not directly involved in the study prepared the randomiza-
tion. Randomization was stratified by study site using blocks
of ten to ensure equal distribution in the two groups.
Allocation was concealed until time of assignment when
the provider opened the next consecutively numbered
opaque envelope.
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performance and acceptability of using MLPT and HSPT
at home to identify continuing pregnancy at 3, 7 and 14 days
after mifepristone. The sample size estimates were based on
evidence from prior studies on the performance of MLPT
and HSPT on days 7 and 14 [4,16,17]. We assumed that the
test specificity at each time point would be 75% (MLPT)
versus 10% (HSPT) on day 3, 99% (MLPT) versus 25%
(HSPT) on day 7 and 99% (MLPT) versus 35% (HSPT) on
day 14. We sought a total of 12 continuing pregnancies.
Using evidence from five randomized trials that included 97
continuing pregnancies among 3702 cases of medical
abortion conducted in Vietnam [16–17,21–23], we assumed
the rate of continuing pregnancy would be 2%. Therefore we
enrolled 600 women (300 per group).
Data entry and analysis were performed using Statistical
Package for the Social Sciences 15.0 and Stata SE 12.1. The
study investigators entered and cleaned the data in Vietnam.
Analysis and findings are reported according to the
CONSORT guidelines [24]. Group differences were assessed
using Pearson's chi-square for categorical variables. p-values
b0.05 were considered statistically significant. For both tests,
we calculated sensitivity (for MLPT: proportion with
continuing pregnancies whose test results showed stable or
increasing hCG; for HSPT: proportion with continuing
pregnancies who obtained a yes in the follow-up test),
specificity (for MLPT: proportion with absence of continuing
pregnancy whose test results showed declining hCG; for
HSPT: proportion with absence of continuing pregnancy who
obtained a “no” in the follow-up test), positive predictive value
(PPV— for MLPT: proportion with stable or increasing hCG
who had a continuing pregnancy, for HSPT: proportion with a
yes result in the follow-up test who had a continuing
pregnancy) and negative predictive value (NPV — for
MLPT: proportionwith declining hCGwho had no continuing
pregnancy, for HSPT: proportion with a “no” result in the
follow-up test who had no continuing pregnancy). For
calculations of test accuracy, we included cumulative results
for all women who used at least one at-home follow-up test.
We excluded 63 participants (MLPT=9, HSPT=54) who did
not use a test on the designated day and had received a false
positive (e.g., for the MLPT group, no ongoing pregnancy
after a stable or rising hCG) from the analyses shown in Table
2 and Fig. 2.3. Results
Fig. 1 shows participant flow; 16 participants (2.6%)were lost
to follow-up. Table 1 summarizes the background and clinical
outcomes of the 600 study participants. There were no
discernable differences in background characteristics or abortion
outcomes between the two study groups. All known outcomes
were ascertained at clinic visits, womenwith unknown outcomes
are listed as lost to follow-up. None of those lost to follow-upwere seen in other departments of the study hospitals for
abortion-related care.
Thirteen women (7 = MLPT, 6 = HSPT) presented with
continuing pregnancy during the study period. Twelve of
these women enrolled with a gestational age≤49 days. Of the
seven women with ongoing pregnancies in the MLPT group,
one presented after using her first follow-up test on study day 3
with a stable hCG reading of≥10,000 mIU/mL. Five women
presented after using a second test on day 7 due to stable or
increasing hCG (and/or concerns about pregnancy symptoms),
and one presented on day 14 after consecutive readings of
≥500 mIU/mL at baseline and study days 3 and 7 and a
reading of ≥2000 mIU/mL at study day 14.
Among the six women with ongoing pregnancy assigned
to HSPT, three presented after they used their home
pregnancy test on day 7 due to concern about the test result
and/or pregnancy symptoms and the remaining three
presented on study day 14 per study protocol.
Some women in both groups presented and had no ongoing
pregnancy. These women had returned early for an unsched-
uled visit mainly due to anxiety about their test results. In the
MLPT group, five (1.7%) women returned due to results that
were stable (i.e., not decreasing) in successive tests. In the
HSPT group, 56 (19.3%) women returned due to a false
positive test result. These women were given reassurance and
instructions to use the next pregnancy test at home per the
study protocol. Women with persistent nonviable pregnancy
or sac (MLPT=10, HSPT=9) were treated with either vacuum
aspiration (n=10) or additional misoprostol (n=9). One
woman with gestational age 42 days in the HSPT group had
an ectopic pregnancy identified at an unscheduled visit. She
took her first home pregnancy test on study day 3 obtaining a
positive result and presented for an unscheduled visit a few
days later due to abdominal pain and bleeding. She
subsequently had surgery for ruptured ectopic pregnancy.
The performance of each test in identifying abortion
outcomes (continuing pregnancy or absence of continuing
pregnancy) is summarized in Tables 2 and 3. Both tests had
100% sensitivity and NPV at all three time points. There
were notable differences, however, in specificity both
between groups and over time, demonstrating large varia-
tions at each time point in favor of MLPT. The PPV was low
at each time point, particularly at study days 3 and 7, due to
the large number of false positives in both groups.
Fig. 2 shows the proportion of women for whom
clinic-based follow-up would be recommended at each
time point based on their test results. There were large
differences in need for follow-up between the two study
groups at each time point with the MLPT enabling two thirds
of women to avoid clinic follow-up after study day 3.
Participant views are summarized in Table 4. The vast
majority in both groups found their respective tests easy to
use and would select home follow-up with a pregnancy test
for managing future abortion follow-up. There were no
significant differences between study groups in any
acceptability measures.
Assessed for eligibility (n=2177)
Excluded (n=1577)
Not meeting inclusion criteria (n=34)
Declined to participate (n=1075)
Other reasons, e.g. due to limited staff, 
not all eligible women could be 
enrolled (n= 468)
Test done 7 days after mifepristone (n=151)
Exited study after the 1st MLPT (n=118)
Test not done for other or unknown reason*
(n=24)
Test done 3 days after mifepristone (n=292)
Assigned to MLPT (n=300)
Received mifepristone & baseline MLPT at 
clinic (n=300)
Test done 3 days after mifepristone (n=290)
Assigned to HSPT (n=300)
Received mifepristone & baseline HSPT at 
clinic (n=300)
Test done 7 days after mifepristone (n=273)
Exited study after the 1st HSPT (n=12) 
Test not done for other or unknown reason*
(n=6)
Test done 14 days after mifepristone (n=54)
Exited study after the 1st MLPT (n=118) 
Exited study after the 2nd MLPT (n=97)
Test not done for other or unknown reason*
(n=24)
Lost to follow up (n=7)
Analyzed with all data available (n=293)
Test done 14 days after mifepristone (n=184)
Exited study after the 1st HSPT (n=12) 
Exited study after the 2nd HSPT (n=88)
Test not done for other or unknown reason*
(n=6)
Lost to follow up (n=9)
Analyzed with all data available (n=291)
*Indicates either woman forgot to take the test at home or no 
reason given for not taking the test at home.
Randomized 
(n=600)
Fig. 1. Consort flow chart.
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Given the extremely high efficacy of early medical
abortion, most women do not need clinic follow-up to
confirm absence of continuing pregnancy. Our data show
that most women can ascertain their abortion outcome at
home using a simple MLPT. This advance in medical
abortion service delivery could eliminate the need forstandard follow-up with ultrasound and/or serum hCG,
both of which are costly to women and health care systems.
Using MLPTs, more than half of women will know within 3
days that their pregnancy has ended. Seven days after
mifepristone, 90% of women can confirm absence of
evolving pregnancy with the urine test; a small percentage
may not receive that confirmation until day 14. In terms of
service delivery, there are advantages and disadvantages to
Table 1
Study participant characteristics and clinical outcomes.
MLPT
n=300
HSPT
n=300
Mean age in years ± SD (range) 30±6 (17–45) 29±6 (17–46)
Educational attainment: n (%)
Primary (1–5 years) 15 (5.0) 22 (7.3)
Secondary (6–12 years) 203 (67.7) 202 (67.3)
University or higher 82 (27.3) 76 (2.0)
Parity: n (%)
0 77 (25.7) 86 (28.7)
1 89 (29.7) 92 (30.7)
2 116 (38.7) 105 (35.0)
3+ 18 (6.0) 17 (5.7)
Mean gestational age in days ± SD (range) 42±5 (30–61) 42±6 (30–63)
Prior abortion: n (%) 135 (45.0) 117 (39.0)
Baseline hCG range (mIU/mL): n (%)
b25 (0–24)* 0
≥25 (25–99) 0
≥100 (100–499) 2 (0.7) N/A
≥500 (500–1999) 106 (36.2)
≥2000 (2000–9999) 107 (36.5)
N10,000 78 (26.6)
Outcome of medical abortion: n (%)
Complete 276 (94.2) 275 (94.5)
Continuing pregnancy 7 (2.4) 6 (2.1)
Persistent nonviable pregnancy or sac^ 10 (3.4) 9 (3.1)
Surgery for ectopic pregnancy 0 1 (0.3)
Lost to follow-up 7 (2.3) 9 (3.0)
MLPT denotes multilevel pregnancy test; SD, standard deviation.
Percentages have been rounded.
N/A is for data not available as the HSPT does not present hCG values using
these ranges. All baseline hCG values for HSPT were positive (≥25 mIU/
mL).
** Each MLPT result reflects a range of possible hCG values, as specified in
parentheses.
^ Includes 3 women classified as incomplete abortion and 7 classified
as missed abortion. All were managed with either uterine evacuation
(n=10) or additional misoprostol (n=9).
able 3
umulative test accuracy in identifying continuing pregnancy by 14 days of
ifepristone administration.
Ongoing
pregnancy
Ø +
LPT Ø
(e.g., decreasing)
268 0
+
(e.g., stable or increasing)
17 7
Ø +
SPT Ø 144 0
+ 141 6
ote: For each woman, the results used were those of last test taken.
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will receive potentially worrisome false positive results. For
some women and systems, this will pose a barrier, and the
more reliable 7-day follow-up may be preferable. For others,
having peace of mind and closure within a few days is aTable 2
Cumulative test accuracy in identifying continuing pregnancy at 3, 7 and 14 days
MLPT
Day 3 (n=292) Day 7 (n=288) Day 14 (n=283)
Sensitivity 100.0 (59.0–100.0) 100.0 (59.0–100.0) 100.0 (59.0–100.
Specificity 63.9 (58.0–69.4) 90.4 (86.3–93.6) 97.1 (94.4–98.7
PPV 6.4 (2.6–12.7) 20.6 (0.9–37.9) 46.7 (21.3–73.4
NPV 100.0 (98.0–100.0) 100.0 (98.6–100.0) 100.0 (98.6–100.
Data are % (95% confidence interval).
MLPT denotes semiquantitative pregnancy test.
Sensitivity was defined as the proportion of those with continuing pregnancies wh
Specificity was defined as the proportion of those with absence of continuing pregn
of those with positive test results who had a continuing pregnancy. NPV was define
pregnancy.T
C
m
M
H
Nperceived advantage, one that women and services may
prefer.
In this study, we confirmed that HSPT is an unreliable
predictor of absence of continuing pregnancy. In settings
where HSPT is the only accessible test, our study indicates
that it will ascertain absence of continuing pregnancy for
60% of women 2 weeks after mifepristone. This result is
higher than previous reports using HSPT (14). With HSPT
follow-up, it is unlikely that providers will miss a continuing
pregnancy; however, service delivery improvements, such as
shortened time until known abortion outcome and reduced
number of (unnecessary) clinic-based follow-up visits would
not occur.
LSPTs are not commercially available in Vietnam, and
we did not assess this alternative strategy, although such tests
are an option for medical abortion follow-up (9,10,12,25).
Recent research using an LSPT that reads positive with an
hCG of at least 1000 mIU/mL resulted in three ongoing
pregnancies detected in the second trimester [25]. Two of the
seven women with continuing pregnancies in our trial
exhibited endline hCG readings of ≤2000 mIU/mL and
might not have been signaled for follow-up if they had
used an LSPT. In settings with strict upper gestational age
limits for legal abortion, ongoing pregnancy needs be
identified as early as possible in order to offer womenof medical abortion.
HSPT
Day 3 (n=290) Day 7 (n=284) Day 14 (n=236)
0) 100.0 (54.1–100.0) 100.0 (54.1–100.0) 100.0 (29.2–100.0)
) 6.0 (3.5–9.4) 19.8 (15.3–25.0) 62.2 (55.6–68.5)
) 2.2 (0.8–4.7) 2.6 (1.0–5.6) 6.5 (2.4–13.5)
0) 100.0 (80.5–100.0) 100.0 (93.5–100.0) 100.0 (97.5–100.0)
o obtained positive test results.
ancy who obtained negative test results. PPV was defined as the proportion
d as the proportion of those with negative test results who had no continuing
38%
(110/292)
12%
(34/288)
5%
(15/283)
94%
(273/290)
80%
(229/284)
39%
(93/236)
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Day 3 Day 7 Day 14
MLPT
HSPT
Fig. 2. Proportion of women for whom clinic-based follow-up would be
recommended at study days 3, 7 and 14 days using standard follow-up
protocols. Notes: Recommendation for follow-up was defined as indication
of stable or increasing hCG when comparing the current test with the prior
test result (MLPT), or a positive current test result (HSPT) or days 7 and 14;
we assumed that all women who did not take a test on the designated day but
received an accurate result in a previous test would have obtained the same
result on the subsequent day.
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such a possibility.
This study has some limitations. For instance, our
protocol discussed study days as the number of days post
mifepristone; however, the critical issue for hCG testing in
early medical abortion is the number of days post
misoprostol, given that the decline in hCG begins after
taking misoprostol [19,20]. In our study, misoprostol was
administered 24 h after mifepristone, allowing earlier
assessment of abortion status. In settings where misoprostol
is used 48 h later, MLPT follow-up may work better at
different time points. We need more data to better understandTable 4
Participant views of at-home pregnancy test for medical abortion follow-up:
% (n).
MLPT group
n=293
HSPT group
n=291
p-value
Ease of use of test at home
Very easy or easy 291 (99.3) 291 (100.0) 0.369
Neither easy nor difficult 1(0.3) 0
Difficult or not very difficult 1 (0.3) 0
Acceptability of time required to use test at home
Very acceptable or acceptable 291 (99.3) 287 (98.6) 0.407
No opinion 2 (0.7) 4 (1.4)
Unacceptable or very unacceptable 0 0
Preferred location for managing abortion follow-up in future
At clinic 28 (9.6) 25 (8.6) 0.286
At home with pregnancy test 257 (87.7) 263 (90.4)
No preference 8 (2.7) 3 (1.0)
Pearson chi-square for tests of differences between groups.options for the timing of MLPT follow-up. Further, although
the protocol allowed for participation among women with
gestations up to 63 days, the majority had gestations under
49 days. Finally, because the main value of an MLPT in
early abortion follow-up is its ability to detect absence of
continuing pregnancy, future research should consider
including this endpoint as a primary outcome.
The ease with which women were able to use and
interpret this MLPT opens a range of home and/or virtual
follow-up options where clinic access to abortion care is
limited [8]. This strategy also creates an enabling environ-
ment for task sharing in early medical abortion care [26].
Further research will contribute to efforts to further simplify
service delivery models suitable to a range of environments.
The test used in this study is not widely available, and its
potential cost is unknown. The potential of MLPTs for
medical abortion follow-up can only be realized once these
tests are commercially available at minimal cost in settings
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